AGENUS INC Restricted Cash and Cash Equivalents
AGENUS INC (AGEN) had Restricted Cash and Cash Equivalents of $1.71 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Restricted Cash and Investments
us-gaap:RestrictedCashAndCashEquivalents · last filed 2026-08-07
- 2026-06-30: Restricted Cash and Cash Equivalents $1.71M.
- 2026-03-31: Restricted Cash and Cash Equivalents $1.71M.
- 2025-12-31: Restricted Cash and Cash Equivalents $1.71M.
- 2025-09-30: Restricted Cash and Cash Equivalents $1.71M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2026-06-30 | $1.71M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $1.71M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $1.71M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $1.71M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $3.63M 10-Q · filed 2026-08-07 |
| 2025-03-31 | $3.63M 10-Q · filed 2026-05-11 |
| 2024-12-31 | $3.63M 10-Q · filed 2026-08-07 |
| 2024-09-30 | $3.63M 10-Q · filed 2025-11-10 |
| 2024-06-30 | $3.63M 10-Q · filed 2025-08-11 |
| 2024-03-31 | $3.67M 10-Q · filed 2025-05-12 |
| 2023-12-31 | $3.67M 10-K · filed 2026-03-16 |
| 2023-09-30 | $3.67M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $2.67M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $2.67M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $2.67M 10-K · filed 2025-03-17 |
| 2022-09-30 | $2.67M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $2.67M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $2.67M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $2.67M 10-K · filed 2024-03-14 |
| 2021-09-30 | $2.67M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $2.67M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $2.67M 10-Q · filed 2022-05-10 |
| 2020-12-31 | $2.63M 10-K · filed 2023-03-16 |
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 |
| 2018-12-31 | $0.00 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |